The Stock of Endo International plc (NASDAQ:ENDP) closed at $8.64 losing 1.71% in yesterday’s trading session. This company has today made an announcement stating that Par Pharmaceutical has already started shipping vigabatrin for oral solution USP, 500 mg per packet. This was after the U.S. Food and Drug Administration proceeded to approve the Abbreviated New Drug Application and it is expected to help a large number of patients around the globe.
A number of medical experts have said that the generic version of Lundbeck LLC’s Sabril® is indeed the Par’s vigabatrin for oral solution. According to them, it is the only existing available generic version and those in need will have to obtain it through the various certified specialty pharmacies as well as the healthcare providers.
The President of Par Pharmaceutical, Tony Pera opined, “We are pleased to be able to offer patients a cost-effective option to Sabril®.Par’s vigabatrin for oral solution is therapeutically equivalent to the brand and is therefore substitutable. We are proud to continue our tradition at Par of providing high quality, affordable medicines.”
U.S. sales of Sabril® for oral solution were estimated to stand at $329M for the 12 months ended June 2017.The IMS Health data will serve as point of reference for many years to come. Sabril® happens to be Lundbeck’s only registered trademark and Endo International plc has talked about its dedication to providing quality medicines to all those patients requiring its services.
The company’s spokesperson revealed that over the years they had succeeded at helping quite a large number of adults and children- 10 years of age and older. Such persons had been struggling with refractory complex partial seizures (CPS), and the company had seen it fit to serve them with Vigabatrin for oral solution.
It hopes that its remedy will better serve patients in relation to the other forms of treatment that had been employed earlier. Some experts have taken the strong standpoint that indeed the associated benefits will in a major way outweigh the risk of vision loss.
